Abstract
1354
Objectives: To explore the application effect of 68Ga-PSMA11 PET/CT for patients with prostate cancer in the whole course.
Methods: The clinical data of 386 prostate cancer patients who underwent 68Ga-PSMA11 PET/CT at Shanghai Changhai Hospital from January 31, 2019 to December 31, 2019 were retrospectively analyzed. The average age of patients at diagnosis was 66.9±7.97 years, and the median serum prostate-specific antigen (PSA) level at the time of diagnosis was 26.8ng/ml.
Results: Of the 386 prostate cancer patients, 160 were newly diagnosed patients, 157 were receiving radiotherapy or endocrine therapy, and 69 patients had persistently elevated PSA or recurrence after surgery. Of the newly diagnosed patients, 55.6% (89/160) did not have any metastasis. When the patient's PSA>30ng/ml, 69.0% (49/71) of the patients had disease recurrence or metastasis, and 50.7% (36/71) of the patients had bone metastasis. A total of 157 patients received radiotherapy and/or endocrine therapy, 31.8% (50/157) did not find any metastasis, 32.5% (51/157) had pelvic lymph node metastasis, 9.6% (15/157) had prostate bed invasion, 47.1 % (74/157) had bone metastasis, and 19.7% (37/157) had distant lymph node or organ metastasis. For patients with persistently elevated PSA or biochemical recurrence after surgery, 47.8% of patients did not find metastasis or recurrence, respectively, 17.4%, 2.9%, 11.6%, and 5.8% only found pelvic lymph nodes, prostate bed, bone, and distant Lymph node or visceral metastasis, pelvic lymph node and bone metastasis occurred in 10.1% of patients, bone and distant metastasis occurred in 2.9% of patients, and pelvic lymph node and distant metastasis occurred in 1.5% of patients.
Conclusions: For newly diagnosed patients with PSA ≥ 30ng/ml, 68Ga-PSMA11 PET/CT is recommended routinely to confirm whether there is metastasis; for patients undergoing endocrine therapy or radiotherapy, this examination can be used to monitor changes in the disease and find the progress of the disease in time; For patients with elevated PSA or biochemical recurrence after surgery, 68Ga-PSMA11 PET/CT is highly sensitive to recurrence and metastasis. It is recommended to perform this examination to determine whether recurrence or metastasis has occurred.